Navigation Links
Hyperion Therapeutics Elects Lota Zoth to Board of Directors
Date:4/7/2008

SOUTH SAN FRANCISCO, Calif., April 7, 2008 /PRNewswire/ -- Hyperion Therapeutics, Inc., a privately held biopharmaceutical company, today announced that Lota S. Zoth has been elected to the company's Board of Directors. Ms. Zoth formerly served as Senior Vice President and Chief Financial Officer of MedImmune, Inc. with oversight of finance, information technology and public affairs.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070905/AQW076LOGO)

In discussing her appointment, Ms. Zoth commented, "Hyperion's co-promotion agreements and strong product pipeline make it a very attractive opportunity. I look forward to helping the Hyperion team continue to execute on its growth objectives."

Prior to MedImmune, Ms. Zoth was Chief Accounting Officer for PSINet, Inc. and Sodexho Marriott Services, Inc., both of which were publicly-held companies. She also served in various finance executive roles at Marriott International and PepsiCo, Inc. after spending almost a decade at Ernst & Young as an audit executive. Ms. Zoth is a certified public accountant and holds a bachelor's of business administration degree in accounting from Texas Tech University.

"Lota's extensive financial and operational background will be a valuable addition to our Board of Directors," said Chris Rivera, President and Chief Executive Officer of Hyperion Therapeutics, Inc. "We look forward to her contributions as we build out our financing strategies with an eye towards accessing the public markets."

About Hyperion Therapeutics

Hyperion Therapeutics is a fully-integrated specialty therapeutics company committed to becoming a global leader in the development and commercialization of hepatology and gastrointestinal therapies that address orphan or underserved patient populations with unmet medical needs. Hyperion's commercial operations division currently markets two products in the United States for urea cycle disorder. The Company is also conducting two phase II trials, one in the chronic treatment of urea cycle disorder and the other in the treatment of acute hepatic encephalopathy. Hyperion is headquartered in South San Francisco, CA. For additional information, visit http://www.hyperiontx.com.


'/>"/>
SOURCE Hyperion Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Hyperion Therapeutics Announces Enrollment of First Patient in Phase 2 Clinical Trial in Patients With Hepatic Encephalopathy
2. Gamma Secretase Modulators Show Promise in Alzheimers Disease Animal Model Efficacy Studies, According to Research Conducted by TorreyPines Therapeutics
3. Antisense therapeutics scientist out to pull more big deals
4. Vista Partners Initiates Coverage on Arana Therapeutics (ASX: AAH; AIM: AAHx)
5. Transition Therapeutics to Present at Cowen & Company 28th Annual Healthcare Conference
6. Juvaris BioTherapeutics, Inc. Announces the Appointment of Grant E. Pickering as Chief Executive Officer
7. Echo Therapeutics Announces Positive Results from Symphony(TM) Transdermal Continuous Glucose Monitoring System Study at Tufts Medical Center
8. Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and 2007 Fourth Quarter and Year End Financial Results
9. Oracle Healthcare Acquisition Corp. and Precision Therapeutics, Inc. Mutually Terminate Merger Agreement; Oracle Healthcare Acquisition Corp. Cancels Special Meeting
10. Bayer HealthCare and Juvaris BioTherapeutics Announce Major Licensing Agreement
11. Cell Therapeutics, Inc. Announces Issuance of $51.7 Million of New 2012 Convertible Senior Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2017)... ... March 25, 2017 , ... Getting earned media coverage meaningful for ... , All through the year, Garden Media aims to provide material helpful to ... influencers and pitching client’s key messages to gain coveted media placements, Garden ...
(Date:3/24/2017)... ... March 24, 2017 , ... Infectious disease affects billions of ... United States, it’s a threat that is constantly changing and evolving. Mediaplanet's “Fighting ... offers strategies for the healthcare community to help decrease the number of completely ...
(Date:3/24/2017)... ... ... The iaedp Foundation, the premier provider of educational programs and training standards for eating ... of disordered eating, announced today that the 2017 Symposium set a new attendance record ... countries converged on the Green Valley Resort in Las Vegas. , “We are ...
(Date:3/24/2017)... ... 24, 2017 , ... Northridge dentists, Dr. Michel ... sleep apnea and TMJ at their office. TMJ, or temporomandibular joint disorder, has ... type, is increasingly being treated at dental offices with newly developed procedures and ...
(Date:3/24/2017)... Texas (PRWEB) , ... March 24, 2017 , ... ... 2017 the year of enhancements, upgrading their training and leads programs. , In ... University. Reserved for elite sales agents, Performance Partners is designed to teach how ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... Research and Markets has announced the addition of the "Deep ... to their offering. ... The Deep Learning: Drug Discovery and Diagnostics Market, 2017-2035 report examines ... deep learning solutions within the healthcare domain. Primarily driven by the ... solution to generate relevant insights from medical data. ...
(Date:3/24/2017)... , March 24, 2017 Global ... industry including definitions, classifications, applications and industry chain structure. ... market including development history, competitive landscape analysis, and major ... ... spread across 105 pages providing 10 company profiles and ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... their offering. ... provides separate comprehensive analytics for the US, Canada , ... Asia-Pacific , Latin America , and Rest of ... 2022. Also, a six-year historic analysis is provided for these markets. Market ...
Breaking Medicine Technology: